罗氏Roche Holdings（RHHBY）2025年第二季度投资者更新报告「OTC」（英文版）（28页）.pdf

1、Investor Update F.Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations email: Tel.+41 61 68-88880 1/13 Ad hoc announcement pursuant to Art.53 LR Basel,24 July 2025 Roche continues strong momentum with 7%growth(CER)in the first half of 2025 Group sales grew by 7%1 at constant exchange rate

2、s(CER;4%in CHF),driven by strong demand for medicines.Pharmaceuticals Division sales rose by 10%(6%in CHF),with Phesgo(breast cancer),Xolair(food allergies),Hemlibra(haemophilia A),Vabysmo(severe eye diseases)and Ocrevus(multiple sclerosis)being the top growth drivers.Diagnostics Division sales were

3、 stable(-3%in CHF)as strong demand for pathology solutions and blood screening tests offset the impact of healthcare pricing reforms in China.Core operating profit increased by 11%(6%in CHF),driven by higher sales and effective cost management.Core earnings per share showed significant growth of 12%

4、(8%in CHF);IFRS net income jumped by 23%(17%in CHF).Outlook for 2025 confirmed.Highlights:US approval for Susvimo for diabetic retinopathy,a potentially blinding eye disease EU approval for Itovebi for a type of advanced breast cancer and Evrysdi tablet for spinal muscular atrophy CHMP recommendatio

5、n for EU label update for Phesgo for breast cancer to allow at-home administration Advancement of key molecules into phase III development:prasinezumab for early-stage Parkinsons disease and zosurabalpin for life-threatening bacterial infections Positive data on several therapies:Lunsumio and Polivy

6、 combination and Columvi for blood cancer,Tecentriq for lung cancer,Itovebi and Perjeta for breast cancer and fenebrutinib for multiple sclerosis and NXT007 for haemophilia A 2/13 Introduction of innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity Announcement o